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Tumor necrosis factor (TNF)-targeted therapies are increasingly being prescribed in the
management of a variety of inflammatory and autoimmune diseases. The use of this class of
medications also pose risks of developing an assortment of pulmonary side effects including
infections (TB, bacterial, and fungal infections), pulmonary nodules, chronic pneumonitis/
fibrosis, SLE-like reactions, vasculitis, and exacerbations of underlying lung disease. In addition
to surveillance for tuberculosis prior to initiation of TNF-targeted therapy, a high level of vigi-
lance should be maintained during administration for infectious and non-infectious complica-
tions, even years into a patient’s course. The available evidence argues for caution in using
these agents in patients with pre-existing lung disease and heightened suspicion of accelerated
nodule formation in those with pre-existing rheumatoid nodules. Management centers on
excluding infection, identifying confounders (especially methotrexate or pre-existing lung
disease), and promptly discontinuing TNF-targeted therapy. In some instances, invasive proce-
dures (e.g. bronchoscopy or VATS lung biopsy) will be necessary to establish the proper diag-
nosis, and the administration of steroids may be beneficial.
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disease-modifying treatment and relief to patients
suffering from rheumatoid arthritis, inflammatory bowel
disease, and other autoimmune conditions. A growing
number of applications are being explored, including
steroid-refractory asthma.1 The increasing frequency of
prescription and number of indications for these therapies
have been accompanied by a growing number of reported
side effects, with reactivation of tuberculosis as the most
widely acknowledged. We set out to review the infectious
and non-infectious pulmonary complications of TNF-tar-
geted therapy by highlighting five patients seen at our
institution. A MEDLINE search was conducted using the
terms ‘‘anti-TNF therapy and pulmonary,’’ and ‘‘infliximab,
etanercept, or adalimumab and pulmonary.’’
Case 1
A 69-year-old female with overlap syndrome (rheumatoid
arthritis, secondary Sjo¨gren’s syndrome, cutaneous discoid
lupus) was admitted with several days of fever, mental
status change, sore throat, dry cough and hypoxia. She was
treated for community-acquired pneumonia with ceftriax-
one and azithromycin but rapidly deteriorated over the
next 24 h requiring transfer to the intensive care unit for
hypoxemic respiratory failure and shock.
She had been prescribed methotrexate for over a year
and had recently started etanercept for polyarthritis. Her
serologies while in the intensive care unit included a posi-
tive anti-nuclear antibody of 1:40e80 (as high as 1:1280 in
the past), rheumatoid factor 39 IU/ml, and low C4
complement level. Anti-ssA/Anti-Ro, anti-cyclic citrulli-
nated peptide (anti-CCP), Scl-70, U1RNP antibodies were
negative.
A computed tomography (CT) angiogram of the chest
revealed no pulmonary embolism but did show severe
pulmonary edema, diffuse ground glass opacities, focalconsolidation of the right upper lobe along with upper lobe
emphysema and moderate bilateral pleural effusions. Her
prior chest CT was noted to have upper lobe emphysema
and mild basilar reticular markings consistent with fibrosis
(Fig. 1AeD). Infectious workup including 2 bronchoalveolar
lavages (BAL), a thoracentesis and serologic studies were
unremarkable. A video-assisted thoracic surgical (VATS)
biopsy revealed findings consistent with subacute and
chronic fibrosis with extensive histiocytic reaction but
without granulomas or hyaline membranes (Fig. 2). Immu-
nofluorescence and infectious studies were negative. The
presumptive diagnosis was etanercept-induced pulmonary
toxicity vs. exacerbation of pre-existing interstitial lung
disease. The patient was treated with methylprednisolone
(1 g IV daily for 3 days) followed by a slow taper of pred-
nisone over the next 2 months with dramatic improvement
in her clinical picture (weaned off mechanical ventilation
after 3 days) and resolution of her infiltrates over the next
month. At the time of manuscript submission, she remains
asymptomatic from a cardiopulmonary standpoint while on
prednisone 10 mg daily and rituximab for her rheumatoid
arthritis.
Case 2
A 57-year-old female with a history of tobacco use, asthma
and psoriasis presented to pulmonary clinic with 3 months
of cough and dyspnea on exertion. She had been taking
etanercept for the past 6 months for psoriatic rash with
good control of her symptoms. She denied sick contacts,
chest discomfort, fevers, chills, or night sweats. She had
not started any new medications besides etanercept in the
past year and denied environmental or occupational
exposures.
Her physical exam was remarkable for exercise desatu-
ration, diffuse wheezing, lack of accessory muscle use, and
absence of rash. Spirometry revealed severe obstruction
Figure 1 Case 1. A 69-year-old female with rheumatoid
arthritis, Sjo¨gren’s syndrome receiving methotrexate and eta-
nerceptwasadmittedand subsequently intubated forhypoxemic
respiratory failure. Chest CT images 2 years prior to illness (A, B)
and during admission (C,D) are shown for comparison. In C and D
there has been interval development of patchy alveolar infil-
trates (arrows), pleural effusions, and compressive atelectasis.
Figure 2 Case 1. Lung parenchyma with reactive pneumo-
cytes, interstitial inflammatory infiltrate and macrophages
within alveolar spaces.
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administration. Chest CT done in the month prior to
presentation revealed scant areas of nodular opacities in
the right and left upper lobes. The patient was prescribed
oxygen and inhaled corticosteroid, long-acting beta-
agonist, and anticholinergic. IgE level, a-1-antitrypsin
level, quantitative immunoglobulins, sputum for acid fast
bacilli were non-diagnostic.
Her cough resolved after discontinuation of etanercept
but was thought to be potentially related to infection.
Reintroduction of etanercept for flare of her psoriasis was
followed by reoccurrence of cough and hypoxia. She was
given a presumptive diagnosis of etanercept-induced
bronchiolar disease. Her cough and hypoxia completely
resolved after discontinuation of etanercept.
Case 3
A 43-year-old female with rheumatoid arthritis of 25 years
duration complicated by subcutaneous nodules, pulmonary
nodules, Sjo¨gren’s syndrome and Raynaud’s phenomenon
presented to pulmonary clinic with a minimally productive
cough for 2 years and progressive dyspnea on exertion over
the past year. Her arthritic symptoms involving the joints of
her hands, feet, wrists, and ankles were well-controlled
over this time with infliximab, methotrexate, and plaque-
nil. She denied tobacco use or constitutional symptoms. Her
physical examination was notable for a comfortable
appearing woman with prolonged expiratory phase,
peripheral cyanosis, and a subcutaneous nodule over the
extensor surface of her left upper extremity.
Pulmonary function tests (PFTs) were notable for
a moderate fixed obstructive defect, hyperinflation and air-
trapping. High resolution chest CT revealed air-trapping,
bronchiolar infiltrates throughout the upper and lower lung
zones with micronodules unchanged in size from a year
prior.
Over the next 6 weeks her symptoms failed to improve
on inhaled corticosteroid and long-acting beta-agonist.
Sputum for acid-fast bacilli and screen for a-1-antitrypsin
Figure 4 Case 4. A 58-year-old female with rheumatoid
arthritis, Sjo¨gren’s syndrome was referred for cough. Chest CT
revealed a diffuse bronchiolar infiltrate (arrows).
664 K. Thavarajah et al.deficiency were negative. VATS lung biopsy revealed orga-
nizing granulomatous inflammation (Fig. 3). Tissue stains
and cultures were negative. A presumptive diagnosis of
infliximab-induced granulomatous inflammation was made.
Her symptoms improved after discontinuation of infliximab.
Case 4
A 58-year-old female with rheumatoid arthritis, Sjo¨gren’s
syndrome and allergic rhinitis presented with 5 months of
non-productive cough. She denied wheezing, dyspnea on
exertion, constitutional symptoms, chest pain, reflux or
post-nasal drip. She had a minimal smoking history and
denied any relevant occupational or environmental
exposures.
She had been treated with methotrexate for 15 years
prior to its discontinuation close to 8 years ago. Over the
past 9 years, she had been taking etanercept with good
control of her joint pain. Her physical examination was
remarkable for basilar crackles.
Her PFTs were within normal limits. However, her
laboratory studies were remarkable for an elevated eryth-
rocyte sedimentation rate, rheumatoid factor, and anti-
cyclic citrullinated peptide (>60 U/ml). Chest CT showed
progression of bronchiolar infiltrates and bronchiectasis
most prominent in the middle and lower lung fields over the
past year (Fig. 4). There were no pleural effusions,
lymphadenopathy, or cystic changes. A VATS lung biopsy
revealed chronic lymphocytic bronchiolitis with non-
necrotizing granulomatous inflammation. All infectious and
immune studies of lung tissue were negative. A presumptive
diagnosis of etanercept-induced granulomatous bronchio-
litis was made and etanercept was discontinued. Her
symptoms, physical examination findings, and radiographic
abnormalities subsequently resolved and did not recur after
administration of adalimumab.
Case 5
A 63-year-old male with seronegative rheumatoid arthritis
and myelodysplastic syndrome presented with 9 months of
progressive dyspnea. His joint symptoms were well
controlled on etanercept (25 mg subcutaneously twiceFigure 3 Case 3. Lung parenchyma with lymphoplasmocytic
infiltrate and organizing pneumonia.aweek) over the past 5 years. He also complained of pleuritic
chest pain and infrequentdry cough.Hedenied fevers, chills,
recent travel, or change in medication. His examination was
remarkable for room air saturation of 94%, lack of crackles,
wheeze, or accessory muscles of respiration use. Pulmonary
function testswere notable for amoderate restrictive defect
and reduced diffusion capacity. Chest CT revealed mosaic
attenuation (Fig. 5). The patient underwent bronchosocopy
with transbronchial biopsies revealing bronchial tissue with
non-caseating granulomatous and chronic inflammation
(Fig. 6AeB). Tissue stains and cultures were negative forFigure 5 Case 5. A 63-year-old male with rheumatoid
arthritis receiving etanercept was referred for dyspnea. Chest
CT revealed mosaic attenuation.
Figure 6 Case 5. A) Respiratory mucosa with rare multinu-
cleated giant cell (arrow). B) Lung parenchyma with reactive
pneumocytes, interstitial lymphoplasmocytic infiltrate and
epithelioid histiocytes suggestive of loose granuloma.
Pulmonary complications of TNF-targeted therapy 665infection. Four weeks after discontinuation of etanercept,
the patient continued to have shortness of breath. The
patient’s shortness of breath and CT findings resolved with
initiation of prednisone.
Role of TNF and potential mechanisms of TNF-
targeted therapy
Tumor necrosis factor mediates numerous biologic effects,
including fever, shock, tissue inflammation and increase in
acute phase proteins.2 Three FDA-approved anti-TNF thera-
pies are available in the United States (see Table 1).3e6 The
different mechanisms of these drugs may lend rationale to
different defects in response to infection and side effects.
Tumor necrosis factor is produced as a type 2 trans-
membrane protein and subsequently cleaved from the cell
surface by TNF converting enzyme. Both membrane-bound
and soluble TNF can bind and activate the p55 TNF receptor
(TNFR1) and the p75 TNF receptor (TNFR2). In addition, theTNFRs can be released from the cell surface and bind TNF,
acting either as agonists or antagonists of TNF biologic
activity. TNFR1 activation is associated with cytotoxicity,
cell adhesion molecule expression, cell growth inhibition,
stimulation of cytokine and chemokine production,
apoptosis, tissue damage and repair, and germinal center
formation. TNFR2 activation is associated with skin
necrosis, T cell proliferation, apoptosis and thymocyte
proliferation. TNFR1 activation induces NF-kB, providing an
anti-apoptotic signal.7
TNF also plays a key role in response to infection. In the
response to bacteria, TNFR1 mediates the activation,
recruitment, and functional efficacy of immune cells and
the formation of granuloma. Both TNFR1 and TNFR2 play
a role in not only the control of viral and protozoal infec-
tions via apoptosis, but also the pathology associated with
these infections. TNFR1 and to a lesser extent, TNFR2
control candidal infection.8
Whereas the role of TNF in response to infection is well
characterized, the mechanisms underlying non-infectious
complications arising from TNF-targeted therapy are not
established. Mouse models of TNF blockade have revealed
that the p55 TNF receptor (TNFR1) is the primary receptor
in vivo. What has been difficult to reconcile is the role of
TNF in tumor development and anti-tumor immunity in the
appropriate setting. The p75 TNF receptor (TNFR2) has
more limited expression; TNFR2 knockout mice display
abnormal necrosis in response to TNF. TNFR2 can enhance
TNFR1 induced apoptosis and may also play a limited role in
adaptive immunity.9 While TNF plays an important role in
T cell activation via recruitment and activation of antigen-
presenting cells, TNF can also down-regulate T cell
receptor signaling. The absence of this latter role may
explain autoantibody development in patients receiving
TNF-targeted therapy.9,10
Infectious complications
Granulomatous infections
One of the earliest recognized infectious complications of
TNF inhibition was extrapulmonary tuberculosis.11 Since
that time, testing for latent tuberculosis prior to initiation
of TNF inhibition has been advocated. Reactivation tuber-
culosis after inhibition of TNF activity may occur secondary
to impaired macrophage apoptosis (a feature of tubercu-
lous-related granuloma formation).11 In vitro work has
suggested that disseminated histoplasmosis in the setting of
TNF inhibition is secondary to an inappropriate TH1
response.12 In addition, at least 4 case reports of pulmonary
cryptococcosis after initiation of infliximab have been cited
in the literature.13 Case series of Japanese patients treated
with infliximab report a rate as high as 0.38% (15 in 4000) of
suspected or confirmed Pneumocystis jiroveci compared to
0.33% rate of tuberculosis.14
Bacterial infections
TNF-targeted therapy may also increase the risk of newly
acquired bacterial infections. In a review of 60 cases
treated either with infliximab and methotrexate or with
Table 1 Summary of FDA-approved TNF-targeted therapies.
Name Description Mechanism of
action
Usual dosing FDA-approved
indications (approved
label as of 1/08)
Non-infectious
pulmonary adverse
events reported in
the literature
Etanercept,
Enbrel
Human recombinant
form of 2 of human
p75 soluble TNFRs
fused to the Fc
fragment of human
IgG1
Binds soluble
and cell-bound
TNF with high
affinity
(competitively
inhibits binding
to TNFRs)
25 mg SC twice
weekly or 50 mg
SC weekly
Ankylosing spondylitis
Juvenile rheumatoid
arthritis
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Non-caseating granuloma
Interstitial lung disease
Autoimmune disease
Accelerated nodulosis
(in patients with
rheumatoid arthritis)
Infliximab,
Remicade
Human IgG1k spliced
to the murine human
monoclonal anti-TNF
antibody
Binds soluble and
cell-bound TNF
3 mg/kg (in 0.9%
normal saline) IV
over 2 h every
8 weeks
Ankylosing spondylitis
Crohn’s disease
Psoriatic arthritis
Plaque psoriasis
Rheumatoid arthritis
Ulcerative colitis
Interstitial lung
disease
Exacerbation of
underlying
lung disease
Precipitation of
methotrexate
pneumonitis
Diffuse alveolar
hemorrhage (37)
Autoimmune disease
Adalimumab,
Humira
Human recombinant
IgG1 monoclonal TNF
antibody
Blocks
interactions
of TNF with the
p55 and p75 cell
surface TNFRs
40 mg SC every
other week
Ankylosing spondylitis
Crohn’s disease
Psoriatic arthritis
Rheumatoid arthritis
Interstitial lung disease
Autoimmune disease
Exacerbation of
underlying
lung disease
TNFRZ TNF receptor.
666 K. Thavarajah et al.etanercept between 1999 and 2002, Kroesen et al.15
identified 11 patients who developed infections requiring
hospitalization. A review of these 11 cases did not reveal
a predilection for a specific bacteria or pre-disposing
duration of therapy. Five of the 11 patients developed
pneumonia. Of note, the number of serious infections after
initiation of anti-TNF therapy increased.15 A retrospective
study of a large US health care organization showed that
patients receiving TNF-targeted therapy have a two-fold
higher risk of developing a bacterial infection than those
patients receiving methotrexate.16 The case series and
chart review both argue for a heightened suspicion of not
only granulomatous infections but also bacterial infections.
Non-infectious complications
Granulomatous disease
In Cases 3, 4, and 5, our patients had evidence of granu-
lomatous lesions on pathology after infliximab or eta-
nercept administration. All showed improvement in signs,
symptoms, and imaging after change or discontinuation of
TNF-targeted therapy, supporting a causative role of TNF-
targeted therapy
There are several reports of patients developing pulmo-
nary granulomatous inflammation after administration of
etanercept. The features on imaging and pathology are
non-specific. Within 4 months of etanercept therapy,
patients developed ground glass infiltrates and non-caseating granulomas on transbronchial biopsy. Discontinu-
ation of etanercept resulted in prompt improvement. Similar
to our patient in Case 4, one of the patients did not have
recurrence of pulmonary symptoms or findings after initia-
tion of adalimumab for recurrent joint symptoms.17,18
A case series of 4 women on etanercept for refractory
joint symptoms developed new alveolar/ground glass
infiltrates within 4 months and had biopsies showing pat-
chy, predominantly bronchiolocentric, acute fibrinous and
granulomatous pneumonia on pathology.19 At sites of
consolidation, T cells and histiocytes comprise loosely
formed granulomas. The granulomatous lesions were
believed to be different from those of sarcoidosis in that
the lymphocytes were found primarily within, not
surrounding, the granuloma. The infectious workup was
negative. Since pre-existing lung disease was present in 3
of the 4 patients, it is also possible that these findings
represent exacerbation of their pre-existing lung disease.
However, the similarities in findings and temporal course
(within 4 months of starting etanercept) argue in favor of
a drug-induced granulomatous reaction.
The question of whether TNF-targeted therapy induces
sarcoidosis, or a sarcoid-like reaction, remains unan-
swered. Several case reports detail development of
pulmonary and extrapulmonary nodules with symmetrical
mediastinal lymphadenopathy after 18 months to 5 years
of infliximab or etanercept.20e23 On biopsy of skin, lymph
nodes, and/or lung tissue, tightly formed granulomas with
or without necrosis were seen. Infectious workup in each
case, including staining and culture data, were negative
Pulmonary complications of TNF-targeted therapy 667for mycobacteria, bacteria and fungi. Symptoms and
findings resolved either with discontinuation of the TNF-
targeted agent and, in some cases, addition of systemic
steroids.
The presence of pulmonary granulomas raises suspicion
of mycobacterial or fungal infection, sarcoidosis, hyper-
sensitivity pneumonitis or rheumatoid nodules (in patients
with rheumatoid arthritis). While the workup (short of
surgical lung biopsy) does not entirely exclude infection,
the continued resolution of symptoms despite new regi-
mens of immunosuppression argues against infection.
Pulmonary nodules
Rheumatoid nodules havebeen reported to occur in up to 25%
of patients with rheumatoid arthritis. The typical rheuma-
toid nodule consists of a necrotic center enclosed by
macrophages and fibroblasts and an outer layer of mono-
nuclear cells.24 Patients with low disease activity can still
develop rheumatoid nodules, suggesting that the develop-
ment of nodules is based on a different mechanism than the
mechanism responsible for joint inflammation.25 Cunnane
et al.26 reported on 3 patients who had resolution of joint
symptoms but developed accelerated nodule formation
while receiving etanercept. The finding that the nodules
resolved or stabilizedon reduceddosing or discontinuation of
etanercept supports a causative role of etanercept therapy.
Similar reports of etanercept-related nodule development
have been described.27e29 Although the distinction between
etanercept-induced granulomatous inflammation and
sarcoidosis or hypersensitivity pneumonitis can be difficult,
the former is suggested in the presence of well-formed
granulomas, some of which may have necrosis, as well as if
there is prompt resolution once etanercept is discontinued.
Interstitial pneumonitis/fibrosis
There is some evidence that anti-TNF therapy can induce
chronic pneumonitis/fibrosis. One report described 4
patients with rheumatoid arthritis who either suffered from
progression of usual interstitial pneumonitis (3 patients) or
developed bronchiolitis obliterans with organizing pneu-
monia (BOOP) within 3 weeks of the 3rd dose of inflix-
imab.30 The joint symptoms of all 4 patients responded
favorably to infliximab. Infectious workup in all 4 patients
was unrevealing. The 3 patients with underlying lung
disease were either asymptomatic or had stable symptoms
over the year prior to infliximab initiation and progressed to
respiratory failure and death. The pathologic features were
inconsistent with diffuse alveolar damage typically found in
acute exacerbations of usual interstitial pneumonitis.31
None of the patients had received methotrexate, but 2 had
received azathioprine in an attempt to reduce formation of
anti-chimeric antibodies.
Hagiwara et al.32 included these 4 cases in a review of 24
cases of reported acute exacerbations of interstitial lung
disease in patients with rheumatoid arthritis receiving anti-
TNF therapy (etanercept nZ 7; infliximab nZ 17; adalimu-
mab nZ 1).While it is difficult to draw firm conclusions from
this small series, the factors that associated with increased
risk of development of interstitial pneumonitis after initia-
tion of anti-TNF therapy were increased age and underlyinglung disease. Over half of the patients had underlying inter-
stitial lung disease. The range of onset of pulmonary symp-
toms after initation of anti-TNF therapy was 3 weeks to 51
months, with most occurring within 3 months.32
Methotrexate pneumonitis
Our patient in Case 1 raised the concern of potential
interaction between etanercept and methotrexate causing
interstitial lung disease. In most therapeutic trials of
rheumatoid arthritis, the effect of methotrexate alone and
methotrexate with a TNF-targeted agent is compared.
Although one report suggests that co-administration of
methotrexate and infliximab reduces formation of human
anti-chimeric antibodies,33 other studies suggest that
co-administration of infliximab and methotrexate can
potentiate methotrexate pneumonitis. Methotrexate
pneumonitis most commonly presents within 32 weeks of
initiating the drug and has pathologic features that include
1) acute and organizing diffuse alveolar damage and/or 2)
cellular interstitial infiltrates with or without granulomas
on pathology (usually non-caseating). Eight patients
developed pneumonitis after administration of infliximab
despite the fact that seven had been on a stable dose of
methotrexate.32,34 Most patients develop symptoms within
weeks of the 3rd infliximab infusion.35e37 Findings on
pathology consisted of type II pneumocyte proliferation
with fibrin deposition with or without a nodular infiltrate of
lymphocytes, histiocytes, plasma cells, and rare multinu-
cleated giant cells. Further studies are required to better
define the distinguishing features of pneumonitis/fibrosis
caused by methotrexate as compared to TNFa-targeted
therapy as well as to determine whether there is an inter-
active effect between these two agents.
Autoimmune disease
A growing body of literature suggests that TNF-targeted
therapies may cause autoimmune disease. The formation of
new autoantibodies during therapy with anti-TNF agents is
not clearly understood. Anti-nuclear antibody formation rate
varies between 34e95% with infliximab, 11e26% with adali-
mumab, and 11e54%with etanercept in rheumatoid arthritis
patients.33 Proposed mechanisms include non-specific B cell
activation, alteration of apoptosis with subsequent
increased exposure of antigens to the immune system, and
downregulation of C-reactive protein leading to reduction in
clearance of apoptotic debris. Ninety-four percent of
patients with suspected lupus developed positive autoanti-
bodies.38 While the majority of patients who develop auto-
antibodies on TNF-targeted therapy are asymptomatic,
Ramos-Casals et al.38 reported on 226 patients who devel-
oped autoimmune disease manifestations in the setting of
anti-TNFa therapy that included vasculitis (nZ 113), lupus
(nZ 92), and interstitial lung disease (nZ 24). Reports of
interstitial lung disease are more difficult to attribute to
autoimmune disease as positive serology was not required
and patients who had been receiving methotrexate or had
a prior history of interstitial lung disease were also classified
as having autoimmune disease. The occurrence of anti-TNF-
induced systemic lupus syndrome has been reported after
etanercept, infliximab, and adalimumab. Diri et al. recently
668 K. Thavarajah et al.described 3 patients with infliximab-induced lupus-like
syndrome involving the lung and pleura. All three patients
developed positive serology, lymphocytic pleural effusions
and dyspnea with or without pulmonary infiltrates. Symp-
toms and findings resolved with discontinuation of infliximab
and initiation of prednisone in 2 of the patients.39 It appears
that while there is a possibility developing manifestations of
a new autoimmune disease after initiation of TNF-targeted
therapy, there is a larger subset of patients that will develop
positive serology without manifestations of autoimmune
disease.
Summary
TNF-targeted therapies are increasingly being used in the
management of a variety of inflammatory and autoimmune
diseases. The beneficial effects may come at the risk of
developing an assortment of pulmonary side effects
including infections (TB, bacterial, and fungal infections),
pulmonary nodules, chronic pneumonitis/fibrosis, SLE-like
reactions, vasculitis, and exacerbations of underlying lung
disease. The presentation is often not straightforward with
management focused on excluding infection, identifying
confounders (especially methotrexate or pre-existing lung
disease), and promptly discontinuing TNF-targeted therapy.
In some instances, invasive procedures (e.g. bronchoscopy or
VATS lung biopsy) will be necessary to establish the proper
diagnosis, and the administration of steroids may be bene-
ficial. The mechanisms of these side effects are unclear.
However, TNF appears not only to play a role in response to
infection, but also to have a regulatory role in autoimmunity.
In addition to surveillance for tuberculosis prior to initiation
of TNF-targeted therapy, a high level of vigilance should be
maintained during administration for infectious and non-
infectious complications, even years into a patient’s course.
The available evidence argues for caution in using these
agents in patients with pre-existing lung disease and
heightened suspicion of accelerated nodule formation in
those with pre-existing rheumatoid nodules. Further studies
are required to better understand the varied clinical mani-
festations, pre-disposing risk factors, and treatment.
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